MYCL and small cell lung carcinoma: However, Myc- but not Mycn- or Mycl-activation induced sensitivity to the AURK inhibitor, alisertib (Fig. 1e), and other cell cycle checkpoint inhibitors (volasertib, p = 0.006 mock vs. Myc; adavosertib, p = 0.05 mock vs. Myc, two-tailed unpaired t test) similar to patient-derived SCLC cells6,7 (Supplementary Fig. 1f).